Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBT-1 + doxorubicin
- Development stage
- Unknown
- Lead developer
- CBA Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CBT-1 + doxorubicin is a combination therapy designed for metastatic, unresectable sarcoma previously treated with doxorubicin. CBT-1 is an orally administered, bisbenzylisoquinoline small molecule that acts as a potent P-glycoprotein (P-gp/ABCB1) antagonist, inhibiting drug efflux and reversing resistance to chemotherapy. Doxorubicin, an anthracycline antibiotic, is a cytotoxic agent that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. The combination is being developed to overcome P-gp-mediated multidrug resistance in sarcoma, aiming to improve doxorubicin efficacy. The main mechanism is the inhibition of P-gp drug efflux by CBT-1 to enhance doxorubicin's anti-tumor activity[1][3][5][7].
- Brand names
- CBT-1®Adriamycin (for doxorubicin)
- Other names
- CBT-1 + doxorubicin
02
Targets
ABCB1 (P-glycoprotein)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on CBT-1 + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBT-1 + doxorubicin.